Nicoya Life Sciences Expands Access to Gold-Standard SPR with Launch of Revo™ Platform Nicoya Life Sciences, Inc., a recognized leader in advanced biophysical characterization technologies for biologics discovery and development, has announced the launch of Revo™, a next-generation, label-free binding…
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for Fibromyalgia Management Axsome Therapeutics, Inc. a biopharmaceutical company pioneering innovative treatments for central nervous system (CNS) disorders, announced today that the first patient has been dosed in the FORWARD Phase…
Sandoz Secures European Commission Approval for Ondibta® (Insulin Glargine), Reinforcing Leadership in Biosimilars and Diabetes Care Sandoz a global leader in affordable medicines, today announced that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for…
Teva Pharmaceuticals Highlights AJOVY® Efficacy in Pediatric Migraine Following Publication in New England Journal of Medicine Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the New England Journal of Medicine (NEJM)…
Johnson & Johnson Announces Positive Phase 3 Results for TECVAYLI® Monotherapy in Early Relapse Multiple Myeloma Johnson & Johnson a global leader in oncology innovation and multiple myeloma treatment, has announced encouraging topline results from the Phase 3 MajesTEC-9 clinical…
argenx SE a global immunology company focused on developing innovative therapies for patients with severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental Biologics License Application (sBLA) for VYVGART® (intravenous…
FDA Accepts Merck’s New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor Merck, a global leader in science and technology, has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pimicotinib,…
Longer-Term OrigAMI-1 Results Highlight Durable Activity of Amivantamab-Based Regimens in Metastatic Colorectal Cancer Johnson & Johnson has announced encouraging longer-term follow-up results from the Phase 1b/2 OrigAMI-1 clinical study evaluating amivantamab-vmjw, an investigational bispecific antibody targeting both epidermal growth factor…
SAGA Diagnostics Highlights Clinical Validity of Pathlight™ MRD in TNBC During SABCS Presentations SAGA Diagnostics Highlights Clinical Validity of Pathlight™ MRD in TNBC During SABCS Presentations. SAGA Diagnostics®, a leader in blood-based cancer detection and precision oncology, continued to advance…
Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward Clinical Trials With $25 Million Series A1 Financing and New Clinical Advisor Peer-reviewed study in Cell Reports Medicine validates ELANE pathway as a cancer-selective, immune-activating mechanism and supports advancement…